Several trial-focused updates highlighted where oncology development is moving fastest and where strategy is meeting friction. A randomized Phase 2 DeLLphi-309 report on tarlatamab extended dosing interval approaches in small cell lung cancer, signaling potential flexibility for patients already treated with platinum chemotherapy. In pancreatic cancer, a nanoparticle- and delivery-focused case report described a procedural advance aiming to diagnose and treat tumors by reaching the pancreas via a vein when standard sampling pathways aren’t safe. At the opposite end of the signal spectrum, a Phase 3 trial testing an antibody–drug conjugate plus pembrolizumab in PD-L1-high metastatic lung cancer delivered a sobering result: it failed to improve progression-free survival. Taken together, the set shows oncology moving on two parallel tracks—clinical operational refinement and new combinatorial mechanisms—while continuing to screen for biomarker-driven failures.